|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US8143283B1
(en)
*
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
|
US6518281B2
(en)
|
1995-08-29 |
2003-02-11 |
Celgene Corporation |
Immunotherapeutic agents
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
DE69734290T2
(de)
*
|
1996-11-05 |
2006-07-06 |
The Children's Medical Center Corp., Boston |
Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
|
|
JP2002520282A
(ja)
*
|
1998-07-09 |
2002-07-09 |
フランシス エイ． ナーデラ， |
慢性リンパ性白血病の処置のための方法および組成物
|
|
US6235782B1
(en)
*
|
1998-11-12 |
2001-05-22 |
Rifat Pamukcu |
Method for treating a patient with neoplasia by treatment with a platinum coordination complex
|
|
US6235776B1
(en)
*
|
1998-11-12 |
2001-05-22 |
Cell Pathways, Inc. |
Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
|
|
WO2000027404A1
(en)
*
|
1998-11-12 |
2000-05-18 |
Cell Pathways, Inc. |
Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic
|
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
|
CZ20013338A3
(cs)
|
1999-03-18 |
2002-03-13 |
Celgene Corporation |
Substituované 1-oxo-a l,3-dioxoisoindoliny a jejich pouľití ve farmaceutických prostředcích pro sníľení koncentrací zánětlivých cytokinů
|
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
EP1178791A2
(en)
*
|
1999-05-07 |
2002-02-13 |
Johns Hopkins University School of Medicine |
The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
|
|
MY164077A
(en)
*
|
1999-05-13 |
2017-11-30 |
Pharma Mar Sa |
Compositions and uses of et743 for treating cancer
|
|
AU5448300A
(en)
*
|
1999-05-27 |
2000-12-18 |
Rockefeller University, The |
Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
|
|
US7105560B1
(en)
*
|
1999-07-23 |
2006-09-12 |
The Regents Of The University Of California |
Use of etodolac in the treatment of multiple myeloma
|
|
US7105172B1
(en)
*
|
1999-11-18 |
2006-09-12 |
Bolla John D |
Treatment of rosacea
|
|
CN100479862C
(zh)
*
|
2000-04-03 |
2009-04-22 |
参天制药株式会社 |
释放物质和采用该物质的药物释放系统
|
|
EP1282423A2
(en)
*
|
2000-05-11 |
2003-02-12 |
Oklahoma Medical Research Foundation |
Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with ns398 or pdtc
|
|
WO2002009683A2
(en)
*
|
2000-07-27 |
2002-02-07 |
Pharmacia Corporation |
Aldosterone blocker therapy to prevent or treat inflammation-related disorders
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
ATE374609T1
(de)
*
|
2000-11-30 |
2007-10-15 |
Childrens Medical Center |
Synthese von 4-aminothalidomid enantiomeren
|
|
WO2002068414A2
(en)
|
2001-02-27 |
2002-09-06 |
The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Analogs of thalidomide as potential angiogenesis inhibitors
|
|
IL142037A0
(en)
|
2001-03-15 |
2002-03-10 |
Agis Ind 1983 Ltd |
Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
|
|
US6344479B1
(en)
*
|
2001-03-20 |
2002-02-05 |
Farmacon-Il, Llc |
Method of preventing retinopathy of prematurity in a neonate
|
|
CN100353947C
(zh)
*
|
2001-03-28 |
2007-12-12 |
参天制药株式会社 |
以甾体为有效成分的视网膜和脉络膜疾病治疗剂
|
|
ATE428419T1
(de)
*
|
2001-08-06 |
2009-05-15 |
Childrens Medical Center |
Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
|
|
KR20110025239A
(ko)
*
|
2001-09-28 |
2011-03-09 |
산텐 세이야꾸 가부시키가이샤 |
약물-폴리에틸렌글리콜 결합체를 함유하는 안조직 내 주입제
|
|
NZ570777A
(en)
*
|
2002-05-17 |
2009-04-30 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
|
CA2672000C
(en)
*
|
2002-05-17 |
2011-11-29 |
Celgene Corporation |
Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma
|
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US7393862B2
(en)
*
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
|
BR0315316A
(pt)
*
|
2002-10-15 |
2005-08-16 |
Celgene Corp |
Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
|
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US8404716B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
US20040091455A1
(en)
*
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
|
JP2006508950A
(ja)
*
|
2002-10-31 |
2006-03-16 |
セルジーン・コーポレーション |
黄斑変性の治療用組成物
|
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US7354948B2
(en)
|
2002-11-06 |
2008-04-08 |
Celgene Corporation |
Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
|
US7230012B2
(en)
*
|
2002-11-14 |
2007-06-12 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
|
US9006267B2
(en)
*
|
2002-11-14 |
2015-04-14 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
|
UA83504C2
(en)
*
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
|
SG133603A1
(en)
|
2003-09-17 |
2007-07-30 |
Us Gov Health & Human Serv |
Thalidomide analogs as tnf-alpha modulators
|
|
US20080027113A1
(en)
*
|
2003-09-23 |
2008-01-31 |
Zeldis Jerome B |
Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
|
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
|
CA2545128C
(en)
*
|
2003-11-06 |
2010-01-12 |
Celgene Corporation |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
|
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
|
BRPI0509019A
(pt)
*
|
2004-03-22 |
2007-08-07 |
Celgene Corp |
métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit
|
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
|
CA2563207A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
|
|
CA2562715A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
|
MXPA06012278A
(es)
*
|
2004-04-23 |
2007-01-31 |
Celgene Corp |
Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de la hipertension pulmonar.
|
|
PL1765362T3
(pl)
*
|
2004-06-04 |
2012-08-31 |
Scripps Research Inst |
Kompozycje i sposoby do leczenia chorób związanych z neowaskularyzacją
|
|
US20070087977A1
(en)
*
|
2004-11-16 |
2007-04-19 |
Wendye Robbins |
Methods and compositions for treating pain
|
|
CA2587406A1
(en)
*
|
2004-11-16 |
2006-05-26 |
Limerick Neurosciences, Inc. |
Methods and compositions for treating pain
|
|
BRPI0518282A2
(pt)
*
|
2004-11-23 |
2008-11-11 |
Celgene Corp |
uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
|
|
AU2006210787C1
(en)
*
|
2005-02-02 |
2013-01-17 |
Nexgenix Pharmaceuticals, L.L.C. |
Local treatment of neurofibromas
|
|
US7442690B2
(en)
*
|
2005-03-14 |
2008-10-28 |
P & L Enterprise Llc |
Topical treatment for psoriasis
|
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
|
BRPI0613670A2
(pt)
*
|
2005-07-22 |
2011-01-25 |
Procter & Gamble |
composições para redução da incidência de arritmia induzida por fármacos
|
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
|
CA2602577C
(en)
|
2005-10-18 |
2015-03-31 |
Allergan, Inc. |
Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
|
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
EA200901041A1
(ru)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
|
EP1974739A1
(en)
*
|
2007-03-21 |
2008-10-01 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Methods and compounds for modulating inflammatory processes
|
|
WO2009020590A1
(en)
|
2007-08-07 |
2009-02-12 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
|
BRPI0705396B1
(pt)
*
|
2007-12-12 |
2021-10-05 |
Universidade Estadual De Campinas - Unicamp |
Compostos derivados ftalimídicos
|
|
PL2245026T3
(pl)
|
2008-02-07 |
2013-01-31 |
Boehringer Ingelheim Int |
Spirocykliczne heterocykle, leki zawierające te związki, ich zastosowanie i sposób ich produkcji
|
|
JP5539351B2
(ja)
|
2008-08-08 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
|
|
BRPI0901298A2
(pt)
*
|
2009-04-06 |
2011-01-04 |
Ems Sa |
derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias
|
|
US20120295979A1
(en)
*
|
2011-05-03 |
2012-11-22 |
Florida Atlantic University |
Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress
|
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
|
WO2014160702A1
(en)
|
2013-03-25 |
2014-10-02 |
Chs Pharma, Inc. |
Retinopathy treatment
|
|
US8906951B1
(en)
|
2013-06-24 |
2014-12-09 |
Tigercat Pharma, Inc. |
Use of NK-1 receptor antagonists in pruritus
|
|
US9198898B2
(en)
|
2013-06-24 |
2015-12-01 |
Tigercat Pharma, Inc. |
Use of NK-1 receptor antagonists in pruritus
|
|
WO2015116802A1
(en)
|
2014-01-29 |
2015-08-06 |
Otsuka Pharmaceutical Co., Ltd. |
Device-based risk management of a therapeutic
|
|
MA40687A
(fr)
*
|
2014-04-10 |
2017-03-28 |
Ifom Fondazione St Firc Di Oncologia Molecolare |
Méthodes et compositions de traitement de malformation vasculaire
|
|
EP3925609B1
(en)
|
2014-08-22 |
2025-07-30 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
|
WO2016210262A1
(en)
|
2015-06-26 |
2016-12-29 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
|
WO2017081676A1
(en)
*
|
2015-11-09 |
2017-05-18 |
Pharmatwob |
Pharmaceutical compositions and methods for treatment of cancer
|
|
US10513515B2
(en)
|
2017-08-25 |
2019-12-24 |
Biotheryx, Inc. |
Ether compounds and uses thereof
|
|
CN118557697A
(zh)
|
2017-09-14 |
2024-08-30 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于癌症的组合治疗
|
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
|
EP3830093A1
(en)
|
2018-07-27 |
2021-06-09 |
Biotheryx, Inc. |
Bifunctional compounds as cdk modulators
|
|
EP3880669A1
(en)
|
2018-11-13 |
2021-09-22 |
Biotheryx, Inc. |
Substituted isoindolinones
|
|
KR102143531B1
(ko)
*
|
2018-12-20 |
2020-08-12 |
영남대학교 산학협력단 |
탈리도마이드를 유효성분으로 함유하는 가축 육질 개선용 조성물
|
|
WO2021222150A2
(en)
|
2020-04-28 |
2021-11-04 |
Anwita Biosciences, Inc. |
Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
|